Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Shukra Pharmaceuticals Ltd has filed a routine compliance certificate confirming that share dematerialization requests received during Q1 2026 (January to March 2026) have been processed by their Registrar and Transfer Agent, Purva Sharegistry (India) Pvt Ltd. The filing confirms that any share certificates submitted for dematerialization were verified, accepted or rejected as appropriate, and mutilated after processing. Importantly, the detailed shareholding table shows NIL dematerialization activity during this period — no shares were converted from physical to electronic form. This is a standard quarterly regulatory filing required under SEBI regulations and does not indicate any unusual shareholder activity.
No direct impact on shareholders or stock price. This is a routine regulatory compliance filing confirming proper processing of dematerialization requests. The NIL activity simply means no shareholders converted physical shares to demat form during Q1 2026.